溃疡性结肠炎(UC),影响全世界数百万患者,与肠道微生物群的紊乱有关。基于益生菌的治疗积极调节肠道菌群的群落结构被认为是UC的有效干预措施。然而,口服益生菌的递送受到有限的生物活性的限制,短保留时间,复杂的病理状况,和单一的治疗效果。这里,构建用多功能前药涂层装饰的生物工程益生菌以改善上述缺点。葡聚糖硫酸钠诱导的UC小鼠的结果表明,制备的涂层的内在特征整合了肠道微生物保护,结肠靶向药物释放,药物滞留时间延长,和炎症调节。并行,益生菌鼠李糖乳杆菌GG(LGG)可以调节肠道菌群组成,改善上皮屏障功能,从而协同改善UC。这些结果为UC的治疗效果提供了充分的证据,因此,作为UC治疗的潜在治疗策略显示出巨大的希望。
Ulcerative colitis (UC), affecting millions of patients worldwide, is associated with disorders of the gut microbiota. Probiotics-based therapy positively regulating the community structure of gut microbiota is regarded as an efficient intervention for UC. However, oral probiotics delivery is restricted by limited bioactivity, short retention time, complex pathological condition, and single therapeutic efficacy. Here, a bioengineered probiotic decorated with a multifunctional prodrug coating is constructed to ameliorate the aforementioned shortcomings. The results of UC mice induced by dextran sulfate sodium demonstrate that the intrinsic features of the fabricated coating integrate gut microbes protection, colon-targeted drug release, prolonged drug retention, and inflammation regulation. In parallel, the probiotics Lactobacillus rhamnosus GG (LGG) could regulate the composition of the gut microbiota and improve epithelial barrier function, thereby synergistically ameliorating UC. These results provide ample shreds of evidence of the therapeutic effect on UC, therefore, demonstrate a great promise as the potential therapeutic strategy for UC treatment.